Rise Advisors’s Immunic IMUX Stock Holding History

Rise Advisors’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-86	Closed	-$940	–	1597
2025 Q1	$940	Buy	+86	New	+$928	﹤0.01%	1275

Other funds holding IMUX

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Rise Advisors's IMUX Position: Q2 2025 in Review

Rise Advisors sold out of Immunic (IMUX) in Q2 2025, closing a stake of 86 shares — an estimated $940 sold.

Rise Advisors first reported a position in IMUX in Q1 2025 and held it in 1 quarter. The position peaked at $940 in Q1 2025. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2025.

Rise Advisors reported no remaining Immunic position as of Q2 2025 after selling out during the quarter.
Rise Advisors sold 86 Immunic shares in Q2 2025, an estimated $940.
Rise Advisors first reported a position in Immunic in Q1 2025 and held it in 1 quarter.
Rise Advisors's Immunic position peaked at $940 in Q1 2025.
55 funds tracked by Wall St. Rank held Immunic as of Q2 2025.

Based on Rise Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.